Real-world effectiveness of MD1003 (high dose pharmaceutical grade biotin) in patients with progressive MS

被引：0
|
作者：
Faure, J.
Jauffret, J.
Carreau, C. [1 ,2 ]
Legrain, P. [1 ,2 ]
Castex, C. [1 ]
Tourbah, A.
机构：
[1] CHU Reims, Reims, France
[2] Univ Reims, Reims, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P585
引用
收藏
页码：281 / 282
页数：2
相关论文
共 50 条
  • [1] Treatment of progressive MS with MD1003 (high dose pharmaceutical grade biotin): real-world evidence
    Ciron, J.
    Pignolet, B.
    Bucciarelli, F.
    Biotti, D.
    Lerebours, F.
    Dorcet, G.
    Rabadeux, C.
    Freitas, N.
    Bonneville, F.
    Brassat, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 693 - 693
  • [2] Immunomodulation associated with clinical and MRI worsening in patients with progressive MS treated with MD1003 (high dose pharmaceutical grade biotin)
    Pignolet, B.
    Ciron, J.
    Bucciarelli, F.
    Scandella, L.
    Biotti, D.
    Lerebours, F.
    Dorcet, G.
    Rabadeux, C.
    Freitas, N.
    Bonneville, F.
    Brassat, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 467 - 468
  • [3] Results of the Phase 3 SPI2 Study of MD1003 (high dose Pharmaceutical grade Biotin) in Progressive MS
    Cree, Bruce A. C.
    Cutter, Gary
    Wolinsky, Jerry S.
    Freedman, Mark S.
    Comi, Giancarlo
    Giovannoni, Gavin
    Hartung, Hans-Peter
    Sedel, Frederic
    Lublin, Fred
    [J]. NEUROLOGY, 2020, 94 (15)
  • [4] High dose pharmaceutical grade biotin, MD1003, treatment preserves motor performance in a model of progressive neurodegeneration
    Nessler, S.
    Winkler, A.
    van der Meer, F.
    Gargareta, S.
    Cobos, A.
    Stadelmann, C.
    Nave, K. A.
    Brueck, W.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 311 - 311
  • [5] Efficacy and safety results of the phase 3 SPI2 study of MD1003 (high dose Pharmaceutical grade Biotin) in progressive MS
    Cree, B. A. C.
    Cutter, G.
    Wolinsky, J. S.
    Freedman, M. S.
    Comi, G.
    Giovannoni, G.
    Hartung, H. -P.
    Sedel, F.
    Lublin, F.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 46 - 46
  • [6] Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003)
    Collongues, Nicolas
    Kuhle, Jens
    Tsagkas, Charidimos
    Lamy, Julien
    Meyer, Nicolas
    Barro, Christian
    Parmar, Katrin
    Amann, Michael
    Wuerfel, Jens
    Kappos, Ludwig
    Moreau, Thibault
    Seze, Jerome
    [J]. BRAIN AND BEHAVIOR, 2021, 11 (02):
  • [7] Effect of MD1003 (high dose pharmaceutical grade biotin) for the treatment of progressive MS: 48-month follow-up data
    De Seze, J.
    Edan, G.
    Moreau, T.
    Brochet, B.
    Sedel, F.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 287 - 288
  • [8] Effect of MD1003 (high dose Pharmaceutical grade Biotin) in the Treatment of Progressive MS: Earlier Treatment Results in Lower Disability Over 48 Months
    De Seze, Jerome
    Edan, Gilles
    Moreau, Thibault
    Brochet, Bruno
    Sedel, Frederic
    Tourbah, Ayman
    [J]. NEUROLOGY, 2019, 92 (15)
  • [9] Long term effect of MD1003 (high dose pharmaceutical grade biotin) in a cohort of patients with progressive non-active multiple sclerosis
    Donze, C.
    Guyot, M. A.
    Kwiatkowski, A.
    Hautecoeur, P.
    Massot, C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 385 - 385
  • [10] High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study
    Juntas-Morales, Raul
    Pageot, Nicolas
    Bendarraz, Abdelkarim
    Alphandery, Sebastien
    Sedel, Frederic
    Seigle, Stephanie
    Camu, William
    [J]. ECLINICALMEDICINE, 2020, 19
12345